Matching articles for "Penmenvy"
Adult Immunization
The Medical Letter on Drugs and Therapeutics • August 17, 2026; (Issue 1761)
The CDC Advisory Committee on Immunization Practices
(ACIP) recommends certain vaccines for adults residing in
the US. The American Academy of Family Physicians has
also recently published an adult...
The CDC Advisory Committee on Immunization Practices
(ACIP) recommends certain vaccines for adults residing in
the US. The American Academy of Family Physicians has
also recently published an adult immunization schedule.
Recommendations for vaccination against COVID-19 and
seasonal influenza will be reviewed separately.
Comparison Chart: Some Vaccines for Adults (online only)
The Medical Letter on Drugs and Therapeutics • August 17, 2026; (Issue 1761)
...
View the Comparison Chart: Some Vaccines for Adults
Penmenvy — A Second Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • April 14, 2025; (Issue 1726)
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years...
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years old. Penmenvy is the second
pentavalent meningococcal vaccine to become
available in the US; Penbraya was licensed in 2023.